Thrombolysis for acute stroke with special emphasis on the very old: Experience from a single Dutch centre

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 77, Issue 3, 2006, Pages 375-377

  Van Oostenbrugge, Robert ^a   Hupperts, R M M ^a   Lodder, J ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT;

ADULT; AGED; AGING; ARTICLE; BRAIN HEMORRHAGE; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PRIORITY JOURNAL; RANKIN SCALE; RISK BENEFIT ANALYSIS; STROKE; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; AGE FACTORS; AGED, 80 AND OVER; BRAIN DAMAGE, CHRONIC; FEMALE; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; INTRACRANIAL HEMORRHAGES; MALE; RISK ASSESSMENT; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 33644551866     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2005.070292     Document Type: Article

References (15)

1. The NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischaemic stroke. N Engl J Med 1995;333:1581-7.
2. Wardlaw JM, Del Zoppo G, Yamaguchi T, et al. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2003;(3):CD 000213.
3. Warlow CP, Wardlaw JM. Therapeutic thrombolysis for acute ischemic stroke. BMJ 2003;326:233-4.
4. Lindley RI, Wardlaw JM, Sandercock PAG. Alteplase and ischaemic stroke: have new reviews of old data helped? Lancet Neurol 2005;4:254-7.
5. Chiu D, Krieger D, Villar-Cordova C, et al. Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. Stroke 1998;29:18-22.
6. Grond M, Stenzel C, Schmülling S, et al. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke 1998;29:1544-9.
7. Kristine M, Chapman MD, Andrew R, et al. Intravenous tissue plasminogen activator for acute ischemic stroke. A Canadian hospital's experience. Stroke 2000;31:2920-4.
8. Albers GW, Bates VE, Clark WM, et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke. The Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000;283:1145-50.
9. Katzan IL, Furlan AJ, Lloyd LE, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000;283:1189-91.
10. Koennecke HC, Nohr R, Leistner S, et al. Intravenous tPA for ischemic stroke team performance over time, safety, and efficacy in a single-center, 2-year experience. Stroke 2001;32:1074-8.
11. Tanne D, Gorman MJ, Bates VE, et al. Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older: the tPA stroke survey experience. Stroke 2000;31:370-5.
12. Simon JE, Sandler DL, Warwick Pexman JH, et al. Is intravenous recombinant tissue plasminogen activator (rt-PA) safe for use in patients over 80 years old with acute stroke? - The Calgary experience. Age Ageing 2004;33:143-9.
13. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator in acute hemispheric stroke. JAMA 1995;274:1017-25.
14. Hyden P, Brott T, Tilley B, et al. Improved reliability of the NIH Stroke Scale using video training. Stroke 1994;25:2220-6.
15. Kammersgaard LP, Jørgensen HS, Reith J, et al. Short- and long-term prognosis for very old stroke patients. The Copenhagen Stroke Study. Age Ageing 2004;33:149-54.